
Conference Coverage
about 4 hours ago
Invivyd Unveils Measles Antibody Candidate VMS063 at IDWeek 2026about 5 hours ago
Sphingolipid Profiling May Help Distinguish IPF From Fibrotic HPLatest Content

Invivyd Unveils Measles Antibody Candidate VMS063 at IDWeek 2026

GLP-1 Use Tied to Lower Diabetes, CV Risk vs Metformin in Prediabetes

Sphingolipid Profiling May Help Distinguish IPF From Fibrotic HP

FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP

Occasional Cannabis Use Linked to 40% Higher Odds of Stroke

Shorts










Center on Health Equity & Access
All News

Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.

Erythema-based criteria miss skin of color, urging ROSCO phenotyping to improve diagnostic equity in dermatology.

New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.

As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.

Patients on tegoprubart reported fewer transplant-related symptoms and better quality of life at 12 months than those on tacrolimus in phase 2 BESTOW.

Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.

Mayo Clinic case-control study links higher birth weight and childhood obesity to greater non-Hodgkin lymphoma risk, while longer breastfeeding may lower odds.

AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.

A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers

Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.





























